May 19, 2011 – New clinical data presented today at EuroPCR 2011 demonstrate immediate and long-term health-related quality-of-life (HRQoL) benefits for patients receiving the Medtronic CoreValve System from Medtronic Inc. The favorable two-year results from the French CoreValve multicenter prospective study are the largest set of CoreValve HRQoL data and the longest-term HRQoL data available from all transcatheter aortic valve implantation (TAVI) systems.
May 19, 2011 - Neovasc Inc., a developer of novel technologies used to treat vascular disease, reported positive six-month follow-up data for a patient with severe refractory angina who received the Neovasc Reducer product in a “live case” procedure broadcast during the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in September 2010. The data, which showed a marked improvement in the patient’s angina symptoms, was presented today at EuroPCR, a leading European cardiovascular conference.
May 19, 2011 - Results from a study validating Cheetah Medical's noninvasive NICOM system specifically for use in patients with pulmonary hypertension were presented Wednesday, May 18th, at the 2011 American Thoracic Society Annual Meeting in Denver.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
May 19, 2011 - BridgePoint Medical Inc. has announced that they have received clearance of an expanded indication for the CrossBoss Catheter and Stingray System from the U.S. Food and Drug Administration (FDA). The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including chronic total occlusions (CTOs)] prior to PTCA or stent intervention. CTOs are chronically stenosed lesions that completely block a coronary artery – typically for 3 months or longer - and prevent blood circulation to critical areas of the heart.
When a lab is transitioning from transfemoral to transradial cardiac catheterizations, the process can be either encouraging or discouraging to all staff involved. To ease the transition, it might be useful to employ previously implemented ideas, techniques and equipment selections that have had positive outcomes. This article will discuss patient preparation, equipment selection and address common inventory concerns that occur when developing a transradial catheterization program. The ideas and initiatives discussed in this article are those that we undertook at the Jesse Brown VA Medical Center in Chicago and may not reflect other cath labs’ setup. However, most of the concepts are applicable to all catheterization labs.
There are many advantages to using optical coherence tomography (OCT) intravascular imaging. However, interventionalists should not rush to trade in their intravascular ultrasound (IVUS) systems, said Michael R. Jones, M.D., FACC, director of the Central Baptist Hospital Heart and Vascular Institute, Lexington, Ky.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Imaging technology and diagnostic tools for interventional cardiologists have changed dramatically over the past few years with the introduction of optical coherence tomography (OCT), improvements in intravascular ultrasound (IVUS) and pressure guide wires used in fractional flow reserve (FFR). Product innovation and integration of these technologies, as well as a growing base of clinical evidence, are transforming the way physicians diagnose, treat and follow-up patients undergoing percutaneous coronary intervention (PCI).
The biggest trend in cardiovascular ultrasound is the adoption of 3-D/4-D echo systems for better images, more data, better measurement quantification and faster workflow. Other key trends include software to speed workflow with fewer keystrokes and to enhance quantification, miniaturization, increased use of tissue strain imaging and expanded use for operating room and cath lab procedures.
There were 15 abstracts presented describing radial access and intervention during the American College of Cardiology (ACC) and i2 Summit meeting in April in New Orleans. The abstracts focused on some of the most burning issues in current radial research.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
The RIVAL trial shows there is no difference in rates of composite death, myocardial infarction, stroke or major bleeding between radial access and femoral access strategies, but radial access decreased major vascular complications.
May 18, 2011 - The Society for Imaging Informatics in Medicine (SIIM) announces tools and training to help medical informaticsprofessionals stay competitive in a rapidly changing environment. SIIM will provide fundamental, up-to-date education and solutions essential for imaging informatics professionals (IIPs) and their organizations at the society's 2011 annual meeting, June 2-5, in Washington, D.C./National Harbor, Md.
As medicine continues its march away from open surgical procedures to minimally invasive and transcatheter treatments, the cath lab has opened up to new treatment areas beyond the coronaries. Peripheral artery disease (PAD) in the legs has traditionally been the territory of vascular surgeons, but there has been a major transition to transcatheter PAD procedures in the past 10 years, blurring the lines between surgeons and interventionalists.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
May 18, 2011 – The world’s first system to integrate the functional and anatomical modalities of fractional flow reserve (FFR) and optical coherence tomography (OCT) into one platform will be highlighted by St. Jude Medical at the Paris Course on Revascularization (EuroPCR) 2011.
May 18, 2011, – Lantheus Medical Imaging Inc. announced data from a Phase 2 clinical trial that demonstrated positron emission tomography (PET) myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty and diagnostic performance for detecting coronary artery disease (CAD) compared to single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), the current standard for the non-invasive detection of CAD. The data also demonstrated a positive safety profile for PET imaging with flurpiridaz F 18.
May 17, 2011 - Medrad Inc., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance Paclitaxel Coated Balloon Angioplasty Catheter with Paccocathtechnology. The Cotavance catheter is used in percutaneous interventions for the treatment of peripheral arterial disease (PAD) and is approved for balloon dilation of stenotic lesions in the iliac and infrainguinal arteries while applying paclitaxel to the vessel wall to inhibit restenosis. Medrad Interventional has started selling its Cotavance catheter in countries where it has already received regulatory approval, including select European and Middle East countries. The announcement was made in conjunction with the Congress of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris.